Board has recommended final dividend of 25% i.e Re. 0.50/- per share on Equity shares of the face value of Rs. 2/- each for the Financial Year ended March 31, 2026.
ROSSARI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.8 pts less than Nifty Microcap 250 and 6.9 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Rossari Biotech's Board approved FY2026 results showing consolidated revenue of Rs. 23,964 million (up 15% YoY) and profit after tax of Rs. 1,492 million (up 9.4% YoY). Basic EPS stands at Rs. 26.95. The Board recommended a final dividend of 25% i.e. Re. 0.50 per share on equity shares of Rs. 2 face value, payable after shareholder approval at the AGM. Additional key items include appointment of Mr. Udeypaul Singh Gill as Independent Director, allotment of 8,250 equity shares under ESOP 2019, setting up of a new R&D facility in Navi Mumbai, and rescheduling of capacity expansion to a phased approach over two years. The company also sold its Kanjurmarg office for Rs. 250 million, booking a gain of Rs. 192.67 million.
The dividend declaration signals healthy cash flows and rewards shareholders. Strong revenue and profit growth indicate business resilience. The rescheduled capacity expansion and new R&D facility suggest focus on measured growth and innovation.